to achieve market access for the absolute newcomers, such as the first immunotherapy and first ATMP.
The > 500 access cases provided us with the necessary know-how of the diversity in application of assessment criteria between different disease areas.
Our national experience provided our team with vast insight and vision into the evolutionary mechanisms and methodologies of assessment procedures of market access in the Netherlands.
So far, we successfully completed two LOCK procedures and one is currently ongoing.
The most experienced market access consultancy with > 24 years of experience, > 500 market access cases completed and performance in > 40 different disease areas for > 35 different clients.
Though the methodology and criteria are the same, precedents exist showing variety in market access hurdles and outcomes.